Episode
2445: Poolbeg’s Big Biotech Moment? First Patient Dosed Ahead of Key POLB 001 Data
- Podcast
- The Vox Markets Podcast
- Published
- Jul 13, 2026
- Duration seconds
- 500
- Processing state
not_requested- Canonical source
- https://audioboom.com/posts/8926828
Actions
POST https://stenobird.com/v1/public/podcasts/the-vox-markets-podcast-3914537/episodes/2445-poolbeg-s-big-biotech-moment-first-patient-dosed-ahead-of-key-polb-001-data/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-vox-markets-podcast-3914537/2445-poolbeg-s-big-biotech-moment-first-patient-dosed-ahead-of-key-polb-001-data.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Watch on YouTube Poolbeg Pharma has dosed the first patient in its POLB 001 TOPICAL clinical trial, marking the start of a key execution phase for its CRS prevention programme. With UCLH activated, further sites expected, interim data targeted for summer 2026 and partnering discussions ongoing, investors will be watching whether clinical progress can validate the programme’s claimed commercial potential.